Amersham Biosciences (GE Healthcare) has been awarded US Patent No. 6,900,019, "In situ cell extraction and assay method."
Jeffrey Horton is the inventor listed on the patent.
According to its abstract, the patent protects a single-stage, single-vessel cell extraction and assay method which is suitable for the extraction and measurement of a range of different types of analyte which occur as cellular components. The patent also protects kits of reagents suitable for performing cellular extraction and measurement as a single-stage, single-vessel process, the abstract states.
The University of Alberta has been awarded US Patent No. 6,900,021, "Microfluidic system and methods of use."
Inventors listed on the patent are Jed Harrison, Per Andersson, Paul Li, Roderick Szarka, Richard Smith, and Hossein Salimi-Moosavi.
According to its abstract, the patent protects a novel microfluidic device and methods of using the device to conduct in vitro studies on the reaction and effects of various compounds on cells. More particularly, the invention relates to a method for using stop flow in a microfluidic system to study the effect of compounds on individual cells, the patent's abstract states. The patent also provides a method for observing the effects of candidate compounds on leukocyte rolling, the abstract states.
Precision Therapeutics has been awarded US Patent No. 6,900,027, "Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays."
Paul Kornblith is the inventor listed on the patent.
According to its abstract, the patent protects an improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured, and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. The system includes the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation, the abstract states. Practical monolayers of cells may thus be formed to enable meaningful screening of a plurality of treatments and/or agents. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most promising agent and concentration for treatment of a particular patient can be determined. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated, the abstract states.
Becton Dickinson has been awarded US Patent No. 6,900,030, "Device for monitoring cells."
Inventors listed on the patent are Bruce Pitner, John Hemperly, Richard Guarino, Magdalena Wodnicka, David Stitt, Gregory Burrell, Timothy Foley, and Patrick Beaty.
According to its abstract, the patent protects methods for detection and evaluation of metabolic activity of eukaryotic and/or prokaryotic cells based upon their ability to consume dissolved oxygen. The methods utilize a luminescence detection system which makes use of the sensitivity of the luminescent emission of certain compounds to the presence of oxygen, which quenches the compound's luminescent emission in a concentration dependent manner, the abstract states. Respiring eukaryotic and/or prokaryotic cells will affect the oxygen concentration of a liquid medium in which they are immersed. Thus, this invention provides a convenient system to gather information on the presence, identification, quantification, and cytotoxic activity of eukaryotic and/or prokaryotic cells by determining their effect on the oxygen concentration of the media in which they are present, the abstract states.
The University of Hawaii has been awarded US Patent No. 6,900,289, "Physalia fluorescent proteins."
Angel Yanagihara is the inventor listed on the patent.
According to its abstract, the patent protects Physalia fluorescent proteins (PFPs) and, more particularly, PFPs of a [specific] Physalia species, and methods of detecting and isolating PFPs. The patent also protects methods and compositions for using PFPs, including recombinant PFPs, as reporter molecules in in vitro and in vivo biological assays, including screening assays and cellular assays, the abstract states.